Applied Therapeutics, Inc.’s $40 Million Initial Public Offering


Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering of common stock of Applied Therapeutics, Inc.

Citigroup, Cowen, UBS Investment Bank and Baird acted as underwriters in the deal.

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. Its lead product candidate is a novel aldose reductase inhibitor with broad systemic exposure and peripheral nerve permeability that it is developing for the treatment of diabetic cardiomyopathy.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. (Picture), counsel Alain Kuyumjian and associate Dmitriy Molchanov. Partner Michael Farber and associate Joseph M. Gerstel provided tax advice. The intellectual property and technology team included partner David R. Bauer and associate Yifu Chen. Counsel Loyti Cheng provided environmental advice. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Yifu Chen – Davis Polk & Wardwell; Loyti Cheng – Davis Polk & Wardwell; Michael Farber – Davis Polk & Wardwell; Joseph Gerstel – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Alain Kuyumjian – Davis Polk & Wardwell; Dmitriy Molchanov – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Applied Therapeutics;

Author: Ambrogio Visconti